Shots:

• Kronos will receive access to Tempus real-world data & tools to expand its preclinical/clinical development portfolio & retains an option to join Tempus TIME trial network to support patient identification, site activation & enrollment of selected clinical trials
• The new collaboration follows an earlier agreement & will utilize Kronos Bio's expertise in transcriptional regulation & Tempus sequencing capabilities along with both company's computational biology capabilities to advance the clinical program's portfolio including lanraplenib & KB-0742
• Additionally, Tempus will harness the strength of its platform to support the discovery and development of novel cancer therapeutics

  Ref: Globe Newswire | Image: Kronos